Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Open in API
Filings indexed 680 across all filing types
Latest filing 2021-06-19 Regulatory Filings
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 90% confidence The document is a letter addressed to stock exchanges regarding the schedule of analyst and institutional investor meetings. It references Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, which pertains to disclosure of material events and information. The content is about announcing upcoming investor calls and meetings, not a financial report or earnings release. The document length is short (1590 characters) and it is an announcement of meetings rather than a transcript or detailed presentation. Therefore, it fits best under the category of Investor Presentation (IP) as it relates to investor communications and meetings, but since it is only a schedule notice, it is more appropriate to classify it as Regulatory Filings (RNS) because it is a regulatory disclosure about investor meetings rather than a full investor presentation document or transcript.
2021-06-19 English
Related Party Transactions
Interim / Quarterly Report Classification · 95% confidence The document is a disclosure of related party transactions for the half year ended March 31, 2021, submitted pursuant to SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. It contains detailed financial data on transactions with related parties during the half year period, including amounts and nature of transactions. The document is not an announcement of a report but contains substantive financial data and analysis for a half year period. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H2 2021
2021-06-19 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 90% confidence The document is a letter addressed to stock exchanges regarding the schedule of analyst and institutional investor meetings. It references compliance with SEBI regulations and provides dates and types of meetings. There is no financial data, report content, or detailed presentation included. The document is an announcement of upcoming investor meetings rather than a report or detailed financial disclosure. Therefore, it fits best under Investor Presentation (IP) as it relates to investor communications and meetings, but since it only announces the schedule and does not contain a presentation itself, it is more appropriate to classify it as Regulatory Filings (RNS) which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2021-06-11 English
Reply to Clarification- Financial results
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India Limited regarding clarification on financial results. It references SEBI regulations and accounting standards (Ind AS 108) related to segment reporting. The letter clarifies that the company operates in a single business segment and explains the disclosure approach for standalone and consolidated financial results for the quarter and year ended March 31, 2021. The document does not contain actual financial statements or detailed financial data but is a regulatory communication clarifying aspects of previously published financial results. The document length is short (2470 characters) and it serves as a clarification rather than a full financial report. Therefore, it fits best under Regulatory Filings (RNS) as a regulatory announcement or clarification rather than an Interim Report (IR) or Annual Report (10-K).
2021-06-10 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the schedule of analyst and institutional investor meetings. It references Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, which pertains to disclosure of material events and information. The content is about announcing upcoming investor meetings, not a financial report, earnings release, or any detailed financial data. The document length is short (1573 characters), and it is an announcement of meetings rather than a report or transcript. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-06-07 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges notifying the schedule of upcoming analyst and institutional investor meetings. It references regulatory compliance (SEBI Listing Obligations) and provides dates and types of meetings. There is no financial data, no report attached or published, and no detailed presentation content. The document is an announcement of meetings with investors and analysts, which fits the category of Investor Presentation announcements or updates. However, since it only lists the schedule of meetings without detailed presentation content, it is best classified as a Regulatory Filing (RNS) because it is a regulatory disclosure about investor meetings rather than the presentation itself.
2021-05-29 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.